Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2020

Nov 10, 2020

30718_dirs_2020-11-10_fdd4dac8-9b44-40fc-ae30-ec522853b489.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2020-11-06

Reporting Person: HIGGINS JOHN L (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-11-06 Common Stock M 5000.00 $70.35 Acquired 9412.00 Direct
2020-11-06 Common Stock S 1450.00 $298.9765 Disposed 7962.00 Direct
2020-11-06 Common Stock S 450.00 $299.8392 Disposed 7512.00 Direct
2020-11-06 Common Stock S 3100.00 $301.0647 Disposed 4412.00 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-11-06 Stock Option (Right to Buy) $70.35 M 5000.00 Disposed 2021-10-26 Common Stock (5000.00) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $201.64 2029-10-24 Common Stock (2011.00) 2011.00 Direct
Stock Option (Right to Buy) $179.84 2028-10-25 Common Stock (1898.00) 1898.00 Direct
Stock Options (Right to buy) $125.05 2027-10-27 Common Stock (3125.00) 3125.00 Direct
Stock Option (Right to Buy) $101.19 2026-10-26 Common Stock (3985.00) 3985.00 Direct
Stock Option (Right to Buy) $87.34 2025-10-28 Common Stock (4260.00) 4260.00 Direct
Stock Option (Right to Buy) $91.78 2024-10-30 Common Stock (4000.00) 4000.00 Direct
Stock Option (Right to Buy) $87.39 2023-10-30 Common Stock (4000.00) 4000.00 Direct
Stock Option (Right to Buy) $66.90 2022-10-24 Common Stock (5000.00) 5000.00 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.5100 to $299.2800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.6050 to $300.4491, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.9950 to $301.0647, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.